Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wouter Jukema

Showing results (541-550 of 927) with videos related to

Pageof 93
Sort By:
Circulation|May 7, 2008
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatinWilleke de Haan, Jitske de Vries-van der Weij, José W A van der Hoorn, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|August 10, 2010
Incremental prognostic value of left ventricular function analysis over non-invasive coronary angiography with multidetector computed tomographyFleur R de Graaf, Jacob M van Werkhoven, Joëlla E van Velzen, et al.
Atherosclerosis|February 12, 2008
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPEREliana Polisecki, Hind Muallem, Nobuyo Maeda, et al.
European Journal of Preventive Cardiology|February 8, 2025
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndromeGregory G Schwartz, Michael Szarek, Esther Reijnders, et al.
Journal of the American College of Cardiology|December 19, 2006
Relationship between noninvasive coronary angiography with multi-slice computed tomography and myocardial perfusion imagingJoanne D Schuijf, William Wijns, J Wouter Jukema, et al.
Circulation. Genomic and Precision Medicine|April 2, 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular MedicineDavid Rhainds, Chris J Packard, Mathieu R Brodeur, et al.
European Journal of Preventive Cardiology|March 19, 2024
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMESMichael Szarek, Esther Reijnders, Ph Gabriel Steg, et al.
Circulation|November 15, 2017
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)Marc P Bonaca, Patrice Nault, Robert P Giugliano, et al.
Atherosclerosis|April 27, 2017
Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosisSabine M J Welten, Rob C M de Jong, Anouk Wezel, et al.
Journal of the American College of Cardiology|March 26, 2024
Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart DiseaseRalph M L Neijenhuis, Simon T MacDonald, Filip Zemrak, et al.
Pageof 93

Showing results (541-550 of 927) with videos related to

Sort By:
Pageof 93
Circulation|May 7, 2008
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatinWilleke de Haan, Jitske de Vries-van der Weij, José W A van der Hoorn, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|August 10, 2010
Incremental prognostic value of left ventricular function analysis over non-invasive coronary angiography with multidetector computed tomographyFleur R de Graaf, Jacob M van Werkhoven, Joëlla E van Velzen, et al.
Atherosclerosis|February 12, 2008
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPEREliana Polisecki, Hind Muallem, Nobuyo Maeda, et al.
European Journal of Preventive Cardiology|February 8, 2025
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndromeGregory G Schwartz, Michael Szarek, Esther Reijnders, et al.
Journal of the American College of Cardiology|December 19, 2006
Relationship between noninvasive coronary angiography with multi-slice computed tomography and myocardial perfusion imagingJoanne D Schuijf, William Wijns, J Wouter Jukema, et al.
Circulation. Genomic and Precision Medicine|April 2, 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular MedicineDavid Rhainds, Chris J Packard, Mathieu R Brodeur, et al.
European Journal of Preventive Cardiology|March 19, 2024
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMESMichael Szarek, Esther Reijnders, Ph Gabriel Steg, et al.
Circulation|November 15, 2017
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)Marc P Bonaca, Patrice Nault, Robert P Giugliano, et al.
Atherosclerosis|April 27, 2017
Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosisSabine M J Welten, Rob C M de Jong, Anouk Wezel, et al.
Journal of the American College of Cardiology|March 26, 2024
Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart DiseaseRalph M L Neijenhuis, Simon T MacDonald, Filip Zemrak, et al.
Pageof 93